查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988337

分子诊断市场自动化：按产品类型、技术、自动化程度、应用和最终用户分類的全球市场预测，2026-2032 年

Automation in the Molecular Diagnostics Market by Product Type, Technology, Automation Level, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年自动化分子诊断市值为157.8亿美元，预计2026年将成长至183.9亿美元，复合年增长率为16.66%，到2032年将达到464.2亿美元。

主要市场统计数据
基准年 2025 157.8亿美元
预计年份：2026年 183.9亿美元
预测年份 2032 464.2亿美元
复合年增长率 (%) 16.66%

分子诊断自动化如何重新定义临床和研究环境中的检查室工作流程、品质期望和策略重点。

在分子检查室中，自动化不再只是循序渐进的改进，而已成为影响临床处理能力、资料完整性和营运韧性的策略必需品。机器人技术、整合样本处理和云端数据分析的进步，以及不断变化的临床需求，共同创造了一个有利于检查室缩短处理时间、标准化通讯协定并提供更快、更可重复结果的环境。因此，自动化不仅影响日常运营，也影响资本投资规划、人才培育和供应商选择。

分子诊断领域正在发生重大变革，而推动变革的因素包括整合自动化、可互通软体以及不断变化的临床和营运需求。

在分子诊断领域，技术成熟、工作流程整合和不断变化的临床需求正在推动变革。定序平台和高通量PCR系统如今已与微阵列解决方案和从检体到结果的先进数据分析工具相辅相成，使检查室能够扩展检测项目并缩短週转时间。同时，软体编配和基于云端的分析技术能够以更高的透明度和可审计性管理复杂的多仪器工作流程。

评估美国关税政策变化对诊断设备製造商和检查室。

美国近期关税趋势和贸易政策的变化正在影响分子诊断设备、耗材和软体的采购和供应。检查室和诊断设备供应商面临着不断变化的成本结构，这影响着他们的供应商选择、库存策略和合约谈判。随着关税改变进口零件和成品的相对经济效益，各机构正在重新评估其供应商所在地，并探索替代製造地和本地库存策略，以降低风险并维持医疗服务的连续性。

全面的細項分析揭示了产品类型、最终用户、技术、自动化程度和应用如何决定采用率、价值和供应商策略。

细分市场分析揭示了产品类型、最终用户、技术、自动化程度和应用领域如何影响整个诊断生态系统的部署模式和价值实现。根据产品类型，所提供的产品涵盖耗材和试剂（包括微阵列晶片、次世代定序(NGS)样品製备试剂盒和 PCR 试剂盒）、仪器（例如微阵列系统、NGS 仪器和 PCR 仪器）以及软体和服务（包括数据分析平台、整合服务和託管服务）。这些类别相互关联；仪器部署通常会推动对耗材的持续需求，而软体和服务则有助于实现更高价值的应用情境和营运扩充性。

区域洞察显示美洲、欧洲、中东和非洲以及亚太地区不同的临床基础设施、采购惯例和法规环境如何影响自动化的采用和商业化。

区域趋势正在影响分子诊断领域的技术应用、报销途径和供应链优先事项。在美洲，先进的检查室网路和一体化参考实验室正在推动对高通量自动化和整合数据平台的需求。同时，对基础设施的投资和对规模化的重视正在促进与以服务和本地支援为重点的供应商建立伙伴关係。相较之下，欧洲、中东和非洲（EMEA）地区的情况则更为复杂。儘管许多市场正在推进法规结构的协调统一和基因组学相关倡议的集中化，但基础设施的差异和分散的采购惯例使得市场需要能够在各种临床环境中运行的灵活模组化解决方案。

主要企业的策略揭示了平台整合、模组化架构、卓越的服务和监管专业知识如何提供竞争优势，并在供应商选择中脱颖而出。

分子诊断自动化领域的主要企业正采用差异化策略，以反映其技术优势、服务模式和打入市场策略。一些供应商优先采用基于平台的方案，将仪器、耗材和软体整合在一起，以确保长期可持续的收入，并确保端到端工作流程的检验。另一些供应商则透过模组化和开放式架构系统来吸引客户，这些系统能够柔软性组合来自多个供应商的仪器。无论采用哪种方案，对连接性、远端监控和生命週期服务的投资都日益成为决定竞争优势的重要因素。

为实验室经营团队和供应商提供实用建议，以使自动化投资与临床优先事项、供应链弹性、劳动力转型和互通性目标保持一致。

产业领导者应采取积极主动的方式，确保在临床、营运和商业领域充分受益于自动化，同时有效管控风险。首先，应透过试点处理大批量、高影响力检测并能缩短处理时间、减少误差且结果可重复的解决方案，使自动化投资与临床优先事项保持一致。同时，应制定人员转型计划，对检查室人员进行再培训，使其掌握自动化监控、数据解读和设备维护等技能，从而最大限度地提高技术投资回报。

结合相关人员访谈、技术检验、二手文献和情境分析，采用严谨的混合方法研究途径，得出了可靠且可操作的见解。

本调查方法整合了第一手和第二手调查、定性访谈以及技术检验，以确保获得可靠且可操作的见解。第一手调查包括对临床、医院、参考实验室、製药和研究机构的实验室经理、采购经理和高级技术人员进行结构化访谈，以收集关于自动化驱动因素、障碍和实施结果的第一手观点。这些访谈为深入分析工作流程需求、人员配置影响和技术选择标准奠定了基础。

结论强调了在整个检查室环境中进行策略性自动化如何改变诊断能力、营运弹性和临床价值的提供。

分子诊断自动化已从一项提升效率的小众措施发展成为检查室策略的核心要素，它影响医疗机构提供诊断、管理风险以及在以价值为导向的医疗环境中竞争的方式。整合自动化减少了人为操作的差异，提高了处理能力，并实现了以往受限于人员和仪器分散的复杂基因组工作流程。因此，策略性地实施自动化的检查室在报告速度、结果可重复性以及将新型检测方法推广到常规操作的能力方面都获得了优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 分子诊断市场：依产品类型划分

  • 耗材和试剂
    • 微阵列晶片
    • NGS样品製备盒
    • PCR试剂盒
  • 装置
    • 微阵列系统
    • NGS设备
    • PCR设备
  • 软体服务
    • 数据分析软体
    • 综合服务
    • 託管服务

第九章 分子诊断市场：依技术划分

  • 微阵列
  • NGS
  • PCR

第十章 分子诊断市场：依自动化程度划分

  • 全自动系统
  • 半自动系统
  • 无人值守自动化

第十一章 分子诊断市场：依应用划分

  • 心血管疾病
  • 基因检测
  • 感染疾病
  • 肿瘤学
  • 女性健康

第十二章 分子诊断市场：依最终用户划分

  • 临床检查室
  • 医院检查室
  • 製药和生物技术公司
  • 标准检验组织
  • 研究所

第十三章 分子诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 分子诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 分子诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国分子诊断市场

第十七章：中国分子诊断市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Adaltis Srl
  • altona Diagnostics GmbH
  • AstraGene LLC
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Hudson Robotics, Inc.
  • Laboratory Corporation of America Holdings
  • MEGAROBO technologies Co., Ltd.
  • Olympus Corporation
  • Synchron Lab Automation
  • Sysmex Corporation
  • Waters Corporation
Product Code: MRR-2D1F5C65740B

The Automation in the Molecular Diagnostics Market was valued at USD 15.78 billion in 2025 and is projected to grow to USD 18.39 billion in 2026, with a CAGR of 16.66%, reaching USD 46.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.78 billion
Estimated Year [2026] USD 18.39 billion
Forecast Year [2032] USD 46.42 billion
CAGR (%) 16.66%

How automation in molecular diagnostics is redefining laboratory workflows, quality expectations, and strategic priorities across clinical and research environments

Automation is no longer an incremental improvement for molecular diagnostics laboratories; it has become a strategic imperative that affects clinical throughput, data integrity, and operational resilience. Advances in robotics, integrated sample processing, and cloud-enabled data analysis are converging with evolving clinical needs to create a landscape where laboratories can reduce hands-on time, standardize protocols, and deliver faster, more reproducible results. As a result, automation influences not only day-to-day operations but also capital planning, workforce development, and vendor selection.

Moreover, the drivers of automation extend beyond simple efficiency gains. Regulatory expectations for traceability and quality, the need to scale testing during infectious disease surges, and the demand for complex genomic assays in oncology and hereditary disease testing all push laboratories toward higher degrees of automation. In turn, suppliers respond with modular architectures, scalable software platforms, and expanded service models. Consequently, stakeholders must view automation as a systems-level change that intersects with clinical strategy, IT infrastructure, and supply chain management.

Key transformative shifts in the molecular diagnostics landscape driven by integrated automation, interoperable software, and evolving clinical and operational demands

The molecular diagnostics landscape is experiencing transformative shifts driven by technology maturation, workflow integration, and changing clinical demand. Sequencing platforms and high-throughput PCR systems now coexist with sample-to-answer microarray solutions and sophisticated data analysis tools, enabling laboratories to broaden their test menus and reduce turnaround times. At the same time, software-enabled orchestration and cloud-based analytics are making it feasible to manage complex multi-instrument workflows with greater transparency and auditability.

Transitioning from fragmented instrument fleets to integrated automation ecosystems also alters procurement approaches and vendor relationships. Suppliers that deliver interoperability, validated workflows, and long-term service agreements gain strategic advantage. Meanwhile, laboratories prioritize solutions that reduce manual interventions, limit contamination risk, and enable remote monitoring. Taken together, these shifts are driving consolidation of point technologies into end-to-end solutions, aligning technical innovation with clinical and operational imperatives.

Assessing how evolving United States tariff policies influence procurement, supply chain resilience, and strategic sourcing decisions across diagnostics manufacturers and laboratories

Recent tariff developments and trade policy changes in the United States have influenced the procurement and supply dynamics for molecular diagnostics equipment, consumables, and software. Laboratories and diagnostic suppliers face an evolving cost structure that affects sourcing choices, inventory strategies, and contractual negotiations. As tariffs alter the relative economics of imported components and finished products, organizations reassess supplier footprints and consider alternative manufacturing locations or local stocking strategies to mitigate exposure and preserve continuity of care.

In response to these trade-induced pressures, industry participants increasingly emphasize supplier diversification and nearshoring. Procurement teams work to redesign contracts with clearer clauses for tariffs, duties, and lead-time variability while supply chain teams collaborate with logistics partners to maintain buffer inventories without sacrificing cold-chain integrity. Concurrently, manufacturers respond by optimizing bill-of-materials, qualifying alternate suppliers, and in some cases accelerating regional manufacturing investments. The cumulative effect reshapes commercial conversations around pricing transparency, service commitments, and risk-sharing arrangements, prompting both buyers and sellers to adopt more resilient, collaborative procurement models.

Comprehensive segmentation insights highlighting how product categories, end users, technologies, automation levels, and applications determine adoption, value, and vendor strategies

Segmentation analysis reveals how product type, end user, technology, automation level, and application areas shape adoption patterns and value realization across the diagnostics ecosystem. Based on product type, offerings range from consumables and reagents-encompassing microarray chips, next-generation sequencing library preparation kits, and PCR kits-to instruments such as microarray systems, NGS instruments, and PCR instruments, as well as software and services that include data analysis platforms, integration services, and managed services. These categories interact: instrument adoption often drives recurring consumable demand while software and services facilitate higher-value use cases and operational scalability.

Based on end user, adoption trajectories diverge among clinical laboratories, hospital laboratories, pharmaceutical and biotechnology companies, reference laboratories, and research laboratories. Each segment prioritizes different performance attributes: clinical laboratories emphasize throughput and regulatory compliance, hospital labs focus on rapid turnaround for patient care, pharmaceutical and biotech customers seek scalability for drug development workflows, reference laboratories value consolidation and automation economies, and research labs often prioritize flexibility and cutting-edge capabilities. Based on technology, choices center on microarrays, NGS, and PCR, with each modality offering distinct trade-offs in sensitivity, resolution, and workflow complexity. Automation level further stratifies the landscape into fully automated systems, semi-automated systems, and walkaway automation, each balancing capital intensity against labor savings. Finally, application areas such as cardiovascular disease screening, genetic testing, infectious disease diagnostics, oncology, and women's health create specialized requirements for sample throughput, assay validation, and data interpretation. By synthesizing these segmentation axes, stakeholders can align product roadmaps, service offerings, and commercialization strategies with the differentiated needs of laboratory segments and clinical applications.

Regional insights illustrating how distinct clinical infrastructure, procurement practices, and regulatory environments in the Americas, EMEA, and Asia-Pacific shape automation adoption and commercialization

Regional dynamics shape technology adoption, reimbursement pathways, and supply chain priorities across the molecular diagnostics landscape. In the Americas, advanced laboratory networks and consolidated reference labs drive demand for high-throughput automation and integrated data platforms, while investments in infrastructure and a focus on scale encourage vendor partnerships that emphasize service and local support. In contrast, the Europe, Middle East & Africa region presents a heterogeneous picture: many markets pursue harmonized regulatory frameworks and centralized genomic initiatives, yet infrastructure variability and fragmented procurement practices require flexible, modular solutions that can operate across diverse clinical contexts.

Meanwhile, Asia-Pacific demonstrates rapid adoption of automation in both centralized and decentralized testing environments, supported by strong domestic manufacturing capabilities in several markets and a growing emphasis on genomic medicine. These regional differences affect vendor go-to-market strategies, with successful suppliers tailoring distribution models, validation packages, and training services to local regulatory regimes and laboratory maturity levels. Consequently, regional insight must inform any commercialization plan, supply chain design, and customer engagement approach to ensure compatibility with local clinical workflows and procurement expectations.

Key company strategies reveal how platform integration, modular architectures, service excellence, and regulatory expertise differentiate competitive positioning and vendor selection

Leading companies in the molecular diagnostics automation space follow differentiated strategies that reflect technological strengths, service models, and route-to-market choices. Some vendors prioritize platform-based approaches that integrate instruments, consumables, and software to lock in long-term recurring revenue and ensure validated end-to-end workflows. Others compete on modularity and open-architecture systems that appeal to customers seeking flexibility and the ability to mix and match instruments from multiple suppliers. Across both approaches, investments in connectivity, remote monitoring, and lifecycle services increasingly determine competitive positioning.

Moreover, successful organizations emphasize regulatory expertise and global service footprints to reduce adoption friction for customers operating across jurisdictions. Partnerships with laboratory networks and strategic alliances with software providers accelerate time-to-implementation and broaden addressable use cases. Additionally, several companies leverage scale in manufacturing and distribution to improve supply reliability and absorb logistical challenges. For buyers, this translates into evaluating suppliers not only on instrument performance but also on their ability to deliver validated workflows, dependable service, and long-term roadmap alignment that supports evolving clinical needs.

Actionable recommendations for laboratory executives and vendors to align automation investments with clinical priorities, supply chain resilience, workforce transformation, and interoperability goals

Industry leaders should adopt a proactive posture to capture the benefits of automation while managing risk across clinical, operational, and commercial domains. First, align automation investments with clinical priorities by piloting solutions that address high-volume, high-impact assays and that demonstrate reproducible gains in turnaround time and error reduction. Simultaneously, develop workforce transition plans that reskill laboratory staff for automation oversight, data interpretation, and instrument maintenance to maximize return on technology investments.

Second, strengthen supply chain resilience through multi-source sourcing strategies, regionally diversified inventory, and contractual terms that account for tariff and logistics variability. Third, prioritize interoperability and data standards when procuring instruments and software to facilitate integration with laboratory information systems and to enable scalable analytics. Fourth, negotiate service-level agreements that include remote diagnostics, preventative maintenance, and clear escalation pathways to minimize downtime. Finally, pursue strategic partnerships with vendors that offer validated workflows and training programs, thereby reducing deployment risk and accelerating clinical adoption. By combining these tactical moves into a cohesive automation roadmap, organizations can sustain operational continuity while unlocking higher-value molecular diagnostics capabilities.

A rigorous mixed-methods research approach combining stakeholder interviews, technical validation, secondary literature, and scenario analysis to produce reliable, application-oriented insights

The research methodology synthesizes primary and secondary evidence, qualitative interviews, and technical validation to ensure robust, actionable insights. Primary research included structured interviews with laboratory directors, procurement leaders, and senior technical staff across clinical, hospital, reference, pharmaceutical, and research laboratory settings to capture firsthand perspectives on automation drivers, barriers, and implementation outcomes. These interviews informed deeper analysis of workflow requirements, staffing implications, and technology selection criteria.

Secondary research drew on peer-reviewed literature, regulatory guidance, company technical documentation, and supply chain data to validate product capabilities, integration standards, and service models. Integrative analysis used cross-validation techniques to reconcile stakeholder testimony with documented performance characteristics and published case studies. In addition, scenario analysis examined procurement and tariff sensitivities, while technology maturity assessments evaluated readiness levels for different automation modalities. Throughout, quality control processes ensured transparency in data sources and reproducibility of conclusions, enabling decision-makers to apply findings with confidence in operational planning and vendor selection.

Concluding synthesis emphasizing how strategic automation adoption transforms diagnostic capability, operational resilience, and clinical value delivery across laboratory environments

Automation in molecular diagnostics has moved from a niche efficiency play to a central element of laboratory strategy, affecting how organizations deliver diagnostics, manage risk, and compete in value-based healthcare settings. Integrated automation reduces manual variability, improves throughput, and enables complex genomic workflows that were previously constrained by labor and instrumentation fragmentation. As a result, laboratories that adopt automation strategically gain advantages in turnaround time, reproducibility, and the ability to scale novel assays into routine practice.

Looking ahead, the interplay between technology providers, laboratories, and regulatory frameworks will determine the pace and pattern of adoption. Organizations that prioritize interoperability, supply chain resilience, and workforce readiness will navigate disruptions more effectively and capitalize on opportunities to extend services and enter new clinical domains. In sum, automation represents both a technological enabler and a business lever; when applied thoughtfully, it transforms laboratory capability and supports higher-quality patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automation in the Molecular Diagnostics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Microarray Chips
    • 8.1.2. Ngs Library Prep Kits
    • 8.1.3. Pcr Kits
  • 8.2. Instruments
    • 8.2.1. Microarray Systems
    • 8.2.2. Ngs Instruments
    • 8.2.3. Pcr Instruments
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Integration Services
    • 8.3.3. Managed Services

9. Automation in the Molecular Diagnostics Market, by Technology

  • 9.1. Microarrays
  • 9.2. Ngs
  • 9.3. Pcr

10. Automation in the Molecular Diagnostics Market, by Automation Level

  • 10.1. Fully Automated Systems
  • 10.2. Semi-Automated Systems
  • 10.3. Walkaway Automation

11. Automation in the Molecular Diagnostics Market, by Application

  • 11.1. Cardiovascular Diseases
  • 11.2. Genetic Testing
  • 11.3. Infectious Disease
  • 11.4. Oncology
  • 11.5. Women's Health

12. Automation in the Molecular Diagnostics Market, by End User

  • 12.1. Clinical Laboratories
  • 12.2. Hospital Laboratories
  • 12.3. Pharmaceutical & Biotechnology Companies
  • 12.4. Reference Laboratories
  • 12.5. Research Laboratories

13. Automation in the Molecular Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automation in the Molecular Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automation in the Molecular Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automation in the Molecular Diagnostics Market

17. China Automation in the Molecular Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Adaltis S.r.l.
  • 18.7. altona Diagnostics GmbH
  • 18.8. AstraGene LLC
  • 18.9. Becton, Dickinson and Company
  • 18.10. Biocartis NV
  • 18.11. bioMerieux S.A.
  • 18.12. Bruker Corporation
  • 18.13. Danaher Corporation
  • 18.14. DiaSorin S.p.A.
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Hologic, Inc.
  • 18.17. Hudson Robotics, Inc.
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. MEGAROBO technologies Co., Ltd.
  • 18.20. Olympus Corporation
  • 18.21. Synchron Lab Automation
  • 18.22. Sysmex Corporation
  • 18.23. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 220. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)